In this study, we proposed the concept of vascular disruption and normalization dependent on a polymeric VDA (poly (L-glutamic acid)-graft-methoxy poly (ethylene glycol)/combretastatin A4, CA4-NPs) + a VEGF/VEGFR2 inhibitor DC101 for improving anti-PD-1 therapy, and investigated the effectiveness and mechanism of CA4-NPs + DC101 in enhancing anti-PD-1 therapy in an H22 tumor model. Here, VEGFA is linked to neoplasm.